Pfizer, Inc. Press Releases

PFE 
$32.71
*  
0.20
0.61%
Get PFE Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading PFE now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Pfizer Hosts Annual Meeting of Shareholders
4/28/2016 12:00:00 PM - Business Wire
▼-0.97 % Price Change since this news event. The Volume Ratio is 1.41.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled
4/26/2016 8:30:00 AM - Business Wire
▼-1.51 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet
4/22/2016 6:30:00 PM - Business Wire
▼-1.95 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders
4/21/2016 2:00:00 PM - Business Wire
▼-1.39 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)
4/19/2016 8:00:00 AM - Business Wire
▲0.28 % Price Change since this news event. The Volume Ratio is 0.93.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






A.M. Best Affirms Ratings of Blue Whale Re Ltd.
4/7/2016 10:47:00 AM - Business Wire
▼-0.34 % Price Change since this news event. The Volume Ratio is 0.65.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care
4/7/2016 8:30:00 AM - Business Wire
▲0.49 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®
4/6/2016 11:00:00 AM - Business Wire
▲1.33 % Price Change since this news event. The Volume Ratio is 1.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Pfizer Announces Termination of Proposed Combination with Allergan
4/6/2016 6:45:00 AM - Business Wire
▲3.51 % Price Change since this news event. The Volume Ratio is 1.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications
4/5/2016 5:34:00 PM - Business Wire
▲3.81 % Price Change since this news event. The Volume Ratio is 1.65.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Remedy Pharmaceuticals Appoints Dr. Thomas R. Zimmerman Jr. as Vice President, Medical Affairs
4/5/2016 9:30:00 AM - Business Wire
▲4.81 % Price Change since this news event. The Volume Ratio is 8.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
4/5/2016 8:00:00 AM - Business Wire
▲3.81 % Price Change since this news event. The Volume Ratio is 7.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
4/5/2016 8:00:00 AM - Business Wire
▲3.78 % Price Change since this news event. The Volume Ratio is 7.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
4/5/2016 7:00:00 AM - Business Wire
▲4.01 % Price Change since this news event. The Volume Ratio is 7.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer and Allergan Issue Statement
4/4/2016 7:05:00 PM - Business Wire


Pfizer and Allergan Issue Statement
4/4/2016 7:05:00 PM - Business Wire


Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing
4/4/2016 9:00:00 AM - PR Newswire
▲8.64 % Price Change since this news event. The Volume Ratio is 1.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
4/1/2016 8:00:00 AM - Business Wire
▲10.51 % Price Change since this news event. The Volume Ratio is 1.33.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day